Opthea Ltd (ASX: OPT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Opthea Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $388.06 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 351.00 million
Earnings per share -0.142
Dividend per share N/A
Year To Date Return -42.45%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Opthea Ltd (ASX: OPT)
Latest News

OPT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Opthea Ltd

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatmentof eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

OPT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $1.11 $0.00 0.00% 657,222 $1.12 $1.16 $1.09
02 Dec 2021 $1.11 $-0.04 -3.48% 589,993 $1.13 $1.13 $1.11
01 Dec 2021 $1.15 $-0.05 -4.18% 470,718 $1.19 $1.20 $1.15
30 Nov 2021 $1.20 $-0.02 -1.65% 283,815 $1.21 $1.22 $1.19
29 Nov 2021 $1.22 $0.01 0.83% 149,033 $1.20 $1.22 $1.20
26 Nov 2021 $1.21 $0.01 0.83% 466,304 $1.20 $1.21 $1.19
25 Nov 2021 $1.20 $0.00 0.00% 192,305 $1.20 $1.22 $1.19
24 Nov 2021 $1.20 $0.01 0.84% 191,729 $1.19 $1.20 $1.17
23 Nov 2021 $1.19 $-0.01 -0.83% 377,340 $1.21 $1.21 $1.19
22 Nov 2021 $1.20 $-0.01 -0.83% 362,346 $1.24 $1.24 $1.19
19 Nov 2021 $1.21 $-0.03 -2.42% 102,239 $1.23 $1.24 $1.21
18 Nov 2021 $1.24 $0.02 1.65% 182,815 $1.22 $1.25 $1.21
17 Nov 2021 $1.22 $-0.02 -1.61% 287,790 $1.26 $1.26 $1.21
16 Nov 2021 $1.24 $0.00 0.00% 169,324 $1.26 $1.26 $1.22
15 Nov 2021 $1.24 $0.02 1.64% 220,721 $1.24 $1.26 $1.24
12 Nov 2021 $1.22 $0.01 0.83% 383,933 $1.22 $1.26 $1.20
11 Nov 2021 $1.21 $-0.04 -3.21% 424,284 $1.26 $1.27 $1.21
10 Nov 2021 $1.25 $-0.02 -1.57% 218,276 $1.27 $1.27 $1.24
09 Nov 2021 $1.27 $0.01 0.79% 302,330 $1.27 $1.27 $1.26
08 Nov 2021 $1.26 $0.01 0.80% 250,086 $1.25 $1.27 $1.23

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
11 Nov 2021 Megan Baldwin Issued 1 $1,936,000
Issue of securities. 1,600,000 - Performance Rights
As per announcement on 11/11/2021.
19 Oct 2021 Judith Robertson Issued 2 $2,560,000
Issue of options.
19 Oct 2021 Julia Haller Issued 2 $2,560,000
Issue of options.
04 Mar 2021 Megan Baldwin Buy 2 $1,368,804
Exercise of options.
04 Mar 2021 Megan Baldwin Exercise 2 $1,368,804
Exercise of options. As per announcement on 05/0/2021.
04 Mar 2021 Michael Sistenich Exercise 712 $342,201
Exercise of options. As per announcement on 05/03/2021.
04 Mar 2021 Michael Sistenich Buy 712 $342,201
Exercise of options.
01 Mar 2021 Daniel Spiegelman Issued 2 $3,160,000
Issue of options.
01 Mar 2021 Jeremy Levin Issued 3 $4,740,000
Issue of options.
01 Mar 2021 Lawrence Gozlan Issued 2 $3,160,000
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Lawrence Gozlan Non-Executive Director Jul 2020
Mr Gozlan's global capital markets experience and knowledge in life science investment. Mr Gozlan is the Life Sciences Investment Manager at Jagen Pty Ltd, a family office. Prior to Jagen, Mr Gozlan was the biotechnology analyst at the Queensland Investment Corporation (QIC) and Foster Stockbroking, and formerly advised life science companies at Deloitte. He currently serves as a Director on several private and public company boards in Australia and the US.
Dr Megan Baldwin Chief Executive OfficerManaging Director Feb 2014
Dr Baldwin brings over 20 years of experience in angiogenesis and therapeutic strategies for cancer and ophthalmic indications. Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech's commercial division and having responsibility for corporate competitive intelligence activities. In these roles, she developed commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development. She is a director of Ausbiotech.
Mr Michael Sistenich Non-Executive Director Nov 2015
Mr Sistenich has advised a range of global institutions, net worth individuals and companies on healthcare investments over the past 20 years. He has experience in healthcare and in international investment management and investment banking. Michael Sistenich is currently Chairman of the board of Enlitic Inc. and previously served as Director of International Equities and Head of Global Healthcare Investments at DWS Investments, Deutsche Bank Frankfurt. Michael has long standing capital market connections and experience in the global healthcare investment community. Mr Sistenich is Chairman of the Risk committee.
Mr Daniel Spiegelman Non-Executive Director Sep 2020
Mr Spiegelman has industry knowledge and has relevant US corporate governance, compliance and financial management experience, having held numerous executive and Board roles, including as Audit and Risk Committee Chair, with several US public and private companies. Mr Spiegelman has experience in the biotechnology industry who has provided strategic financial management and worked in a number of life science companies during his career. Most recently, Mr Spiegelman served as the Executive Vice President, Chief Financial Officer of BioMarin Pharmaceutical from May 2012 to January 2020. He is currently interim CEO of Recardia Therapeutics and Director and Audit Committee Chair of Myriad Genetics, and the privately held companies Tizona Therapeutics and Spruce Biosciences. Mr Spiegelman's prior experience includes several roles at Genentech Inc., including Treasurer, and Chief Financial Officer of CV Therapeutics. Mr Spiegelman previously served as a director of a number of companies, including Cascadian Therapeutics (formerly Oncothyreon) until its merger with Seattle Genetics, Relypsa until its merger with Galenica AG, Anthera Pharmaceuticals, Affymax, Omeros Corporation and Cyclacel Pharmaceuticals. He will also serve as chair of the Risk Committee.
Dr Jeremy Levin Non-Executive ChairmanNon-Executive Director Oct 2020
Ms Judith Robertson Non-Executive Director Jun 2021
Ms Robertson is a life sciences commercial executive with experience in building, leading and launching several commercial organizations and products including launching multiple ophthalmic products for pharmaceutical and biotechnology companies. Ms Judith Robertson, most recently Chief Commercial Officer of Eleusis Ltd, was previously Chief Commercial Officer of Aerie Pharmaceuticals, where she managed the launch of Rhopressa, the first product targeting a new mechanism of action for the treatment of glaucoma in 20 years, and the launch of the combination product Rocklatan. Prior to Aerie, Ms Robertson was Global Commercial Vice President Immunology and Ophthalmology at Johnson and Johnson, Janssen Pharmaceuticals, and Global Vice President Ophthalmology at Novartis (formerly Alcon). Her prior experience also includes several senior executive commercial roles at Novartis, Searle and Bristol Myers Squibb including President and General Manager of Bristol Myers Squibb Canada. In addition to Opthea, Ms Robertson serves on the Board of Durect Corporation, a Nasdaq listed company developing therapies for acute organ injury and chronic liver diseases.
Dr Julia Haller Non-Executive Director Jun 2021
Dr Haller is currently serving as Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital in Philadelphia. Dr Julia Haller serves as Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and is an authority in therapies to treat and prevent blindness, having published over 350 scientific articles and book chapters. She is also on the Board of Directors of Bristol Myers Squibb and President of the John Hopkins Medical and Surgical Association. Dr Haller previously served on the Board of Celgene Corporation (acquired by Bristol Myers Squibb). In addition to serving on numerous boards, Dr Haller serves as chair of the American Ophthalmological Society's Council, vice-chair of the College of Physicians of Philadelphia and chair of the Society of Heed Fellows. She is a member of the National Academy of Medicine and president of the Women in Medicine Legacy Foundation. She has completed her medical training at Harvard Medical School. Her previous appointments include Professor of Ophthalmology, Johns Hopkins University School of Medicine, The Wilmer Eye Institute.
Mrs Karen Adams Company SecretaryVice President of Finance Jun 2021
Karen Adams Company SecretaryVice President of Finance

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 53,144,712 19.74%
HSBC Custody Nominees (Australia) Limited GSCO ECA 29,682,673 11.03%
J P Morgan Nominees Australia Pty Limited 24,030,161 8.93%
Jagen Pty Ltd 13,520,540 5.02%
Armada Trading Pty Limited 13,332,031 4.95%
Hsbc Custody Nominees (Australia) Limited 13,180,132 4.90%
National Nominees Limited 10,706,431 3.98%
Bnp Paribas Noms Pty Ltd 9,821,245 3.65%
UBS Nominees Pty Ltd 8,146,658 3.03%
HSBC Custody Nominees (Australia) Limited A/C 2 7,741,513 2.88%
Cs Third Nominees Pty Limited 6,851,786 2.55%
Mrs Margaret Lynette Harvey 4,000,000 1.49%
Cs Fourth Nominees Pty Limited 2,737,539 1.02%
LL Family Nominees Pty Ltd 2,150,538 0.80%
Just Group Investment Pty Ltd 2,123,239 0.79%
Montoya Pty Limited 1,877,357 0.70%
Merrill Lynch (Australia) Nominees Pty Limited 1,555,260 0.58%
Bnp Paribas Nominees Pty Ltd 1,315,451 0.49%
Sandhurst Trustees Ltd 1,227,991 0.46%
LGL Trustees Limited 1,219,693 0.45%